Treatment of C26 cells with cisplatin (CIS), without PUFAs, showed a dose-dependent decrease in cell viability (CIS > 6.25 μM, P& 0.0001 compared to control) with a significant increase in caspase 3/7 activity which plateaued at 12.5 μM CIS (P& 0.002 for all concentrations compared to control). Here, CASP3 is linked to in situ carcinoma.